Swaza Inc.
Swaza Inc. is a biotechnology company focused on developing revolutionary oxygen nanotherapeutics. Their mission is to provide innovative solutions for respiratory distress through non-invasive nanofluid breathing aids and advanced regenerative biomaterials, leveraging their proprietary nanotechnology platform.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Non-invasive oxygen-carrying nanoemulsion for inhalation
A nanoemulsion-based inhalation formulation designed to draw oxygen from air and actively shuttle O2 and CO2 across fluid and fibrotic barriers at the lung surface to improve gas exchange in damaged lungs.
Oxygen-enriched wound-healing biomaterial
Topical biomaterial engineered to deliver oxygen to burns and ulcers to support healing.
Thermoreversible formulation for emergency rectal oxygenation
A thermoreversible enema formulation intended to provide emergency oxygenation in severe trauma scenarios.
Pulmonary drug delivery platform for fibrotic lungs
Platform enabling delivery of therapeutic molecules to the pulmonary system and across fibrotic barriers to reach diseased tissue.
Non-invasive oxygen-carrying nanoemulsion for inhalation
A nanoemulsion-based inhalation formulation designed to draw oxygen from air and actively shuttle O2 and CO2 across fluid and fibrotic barriers at the lung surface to improve gas exchange in damaged lungs.
Oxygen-enriched wound-healing biomaterial
Topical biomaterial engineered to deliver oxygen to burns and ulcers to support healing.
Thermoreversible formulation for emergency rectal oxygenation
A thermoreversible enema formulation intended to provide emergency oxygenation in severe trauma scenarios.
Pulmonary drug delivery platform for fibrotic lungs
Platform enabling delivery of therapeutic molecules to the pulmonary system and across fibrotic barriers to reach diseased tissue.
Expertise Areas
- Nanoparticle formulation for respiratory therapeutics
- Pulmonary drug delivery across fibrotic barriers
- Oxygen-enriched biomaterials for wound healing
- Preclinical efficacy evaluation (rodent ARDS models)
Key Technologies
- Oxygen-carrying nanoemulsions / nanofluids
- Liquid nanoparticles for gas shuttling (O2/CO2)
- Oxygen-enriched topical biomaterials
- Thermoreversible biomaterial formulations
Key People
Co-Founder & Chief Scientist
Co-Founder & CEO
Chief Technical Officer
Director of Regulatory and Clinical Affairs
Chemistry Manufacturing and Controls
Senior Scientist
Co-Founder & Chief Scientist
Co-Founder & CEO
Chief Technical Officer
Director of Regulatory and Clinical Affairs
Chemistry Manufacturing and Controls
Senior Scientist
News & Updates
Swaza Inc. has announced a partnership with BARDA's DRIVe program to develop a groundbreaking treatment for acute respiratory distress syndrome (ARDS).
Swaza Inc. has announced a partnership with BARDA's DRIVe program to develop a groundbreaking treatment for acute respiratory distress syndrome (ARDS).